Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.330 Biomarker group BEFREE Synergistic treatment of salirasib and Exo2 exhibits a superior inhibitory effect on prostate tumor growth compared with either drug alone, which may be attributed to the more efficient inhibition of ERK1/2 phosphorylation. 28830537 2017
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.330 Biomarker group CTD_human The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. 24763052 2014
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.330 Biomarker group LHGDN Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation. 17695723 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.330 AlteredExpression group LHGDN Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. 17068343 2006